Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial

Abstract : To investigate whether adding bevacizumab to neoadjuvant carboplatin-paclitaxel (CP) helps achieve optimal debulking, measured by complete resection rate (CRR) at interval debulking surgery (IDS), in patients with initially unresectable International Federation of Gynecology and Obstetrics stage IIIC/IV ovarian, tubal or peritoneal adenocarcinoma.
Document type :
Journal articles
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-01658616
Contributor : Christophe Pomel <>
Submitted on : Thursday, December 7, 2017 - 5:22:53 PM
Last modification on : Monday, May 27, 2019 - 10:11:18 AM

Links full text

Identifiers

Citation

Roman Rouzier, Sébastien Gouy, Frédéric Selle, Eric Lambaudie, Anne Floquet, et al.. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. European Journal of Cancer, Elsevier, 2017, 70, pp.133 - 142. ⟨10.1016/j.ejca.2016.09.036⟩. ⟨hal-01658616⟩

Share

Metrics

Record views

331